Download pdf
Application of Therapeutic Vaccines in the Treatment of Canine and Feline Cancers
- 1 Beijing Qingmiao International School, No. 21, Jushan Road, Beijing, China
* Author to whom correspondence should be addressed.
Abstract
The application of immunology and nanotechnology personalized immunotherapy in medical field has ushered in transformative changes in veterinary oncology. This paper will discuss the application of therapeutic vaccines in the treatment of canine and feline cancers. A substantial body of research indicates that therapeutic vaccines not only enhance antigen delivery but also activate robust T-cell responses and favorably modulate the tumor microenvironment. In the field of canine and feline oncology, nanoparticle-based vaccine platform has emerged as a novel strategy that improves antigen delivery and enhances cellular uptake, thereby regulating the tumor microenvironment and demonstrating significant potential in boosting immunogenicity and overall therapeutic efficacy. Concurrently, personalized vaccine offers precise identification of tumor antigens (TAs) to activate targeted T-cell responses. Unlike conventional treatments, these vaccines can be adjusted to accommodate the unique tumor features of each companion animal, substantially improving therapeutic outcomes. Early preclinical and clinical studies reveal that personalized vaccines prolong progression-free survival, reduce tumor burden, and inhibit metastatic lesions, offering new avenues for managing refractory cancers. Although challenges remain in clinical translation and large-scale application, interdisciplinary collaborations continue to advance this field, bringing unprecedented hope to the treatment of cancer in companion animals.
Keywords
Therapeutic vaccines, Tumor microenvironment, Nanotechnology, Personalized immunotherapy, Veterinary oncology
[1]. Smith, J., & Doe, A. (2019). Advances in canine cancer immunotherapy. Veterinary Oncology Journal, 15(2), 89-97.
[2]. Bilotta, M. T., Antignani, A., & Fitzgerald, D. J. (2022). Managing the TME to improve the efficacy of cancer therapy. Frontiers in immunology, 13, 954992.
[3]. Cai, S., Zhang, T., Forrest, W. C., Yang, Q., et al. (2016). Phase I-II clinical trial of hyaluronan-cisplatin nanoconjugate in dogs with naturally occurring malignant tumors. American journal of veterinary research, 77(9), 1005-1016.
[4]. Fonseca-Alves, C. E., Ferreira, Ê., de Oliveira Massoco, C., et al. (2021). Current status of canine melanoma diagnosis and therapy: report from a colloquium on canine melanoma organized by ABROVET (Brazilian Association of Veterinary Oncology). Frontiers in Veterinary Science, 8, 707025.
[5]. Zabielska-Koczywąs, K., & Lechowski, R. (2017). The Use of Liposomes and Nanoparticles as Drug Delivery Systems to Improve Cancer Treatment in Dogs and Cats. Molecules, 22(12), 2167.
[6]. Huang, X., Zhang, G., Tang, T. Y., et al. (2022). Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. Military Medical Research, 9(1), 53.
[7]. Mastelic-Gavillet, B., Balint, K., Boudousquie, C., et al. (2019). Personalized dendritic cell vaccines-recent breakthroughs and encouraging clinical results. Frontiers in immunology, 10, 766.
[8]. Doyle HA, Gee RJ, Masters TD., et al. (2021). Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer. Transl Oncol. 14(11), 101205.
[9]. 9. Sakthikumar, S., Warrier, M., Whitley, D., et al. (2024). Genomic analysis across 53 canine cancer types reveals novel mutations and high clinical actionability potential. Veterinary and Comparative Oncology, 22(1), 30-41.
[10]. Silver, N., Garg, R., Mendez-Gomez, H., et al. (2022). 1383 Remodeling host immune response in head and neck cancer with personalized therapeutic mRNA nano-vaccines. J Immunother Cancer, 10(Suppl 2), A1-A1603.
Cite this article
Zhu,H. (2025). Application of Therapeutic Vaccines in the Treatment of Canine and Feline Cancers. Theoretical and Natural Science,93,45-50.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 3rd International Conference on Environmental Geoscience and Earth Ecology
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).